
Supernus Inc (SUPN) Stock Forecast & Price Target
Supernus Inc (SUPN) Analyst Ratings
Bulls say
Supernus is attractive because the combined company now markets 11 approved therapies across psychiatry, neurology, and addiction medicine, reducing dependence on any single asset while concentrating on durable CNS franchises. Its core growth drivers—Sublocade, Qelbree, Zurzuvae, and Onapgo—have clear commercial momentum and long exclusivity runways, and the cited model points to EBITDA comfortably north of $1B in 2027 with roughly $800M of net debt and only 6x-7x 2027 EBITDA valuation. The outlook is further supported by operating leverage from about $120M of annualized SG&A savings, plus meaningful upside from broadening LAI buprenorphine adoption and continued prescription growth in ADHD, PPD, and Parkinson’s disease.
Bears say
Supernus is facing a difficult mix of patent-cliff risk, competitive pressure, and execution uncertainty that weakens the durability of its earnings base. The disclosure that Gocovri is expected to peak at just over $175M in 2028, then face steep erosion after a June 2029 LOE, underscores how dependent the portfolio still is on a few products while generic competition already pressures the buprenorphine franchise, which has fallen from 20% in 2022 to 14.2% in 2025. Although the company has ongoing programs in depression, treatment-resistant epilepsy, and Parkinson’s disease hypomobility, FDA, commercialization, and financing risks could delay growth and require additional capital or partnerships.
This aggregate rating is based on analysts' research of Supernus Inc and is not a guaranteed prediction by Public.com or investment advice.
Supernus Inc (SUPN) Analyst Forecast & Price Prediction
Start investing in Supernus Inc (SUPN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Supernus Inc (SUPN) Forecast
Supernus Inc (SUPN) Analyst Forecast & Price Prediction
Start investing in Supernus Inc (SUPN)
Order type
Buy in
Order amount
Est. shares
0 shares